

Online Resource Material

Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice

Targeted Oncology

Adam Brufsky, MD, PhD, Xianchen Liu, MD, PhD, Benjamin Li, PhD, Lynn McRoy, MD,

Rachel M. Layman, MD

Corresponding Authors

Dr Adam Brufsky, MD, PhD

Email: brufskyam@upmc.edu

University of Pittsburgh, College of Medicine

Dr Xianchen Liu, MD, PhD

Email: Jasonxc.Liu@pfizer.com

Pfizer Inc

Online Resource 1. Patient Characteristics After Stabilized Inverse Probability of Treatment Weighting

Characteristic	Cohort After Stabilized Inverse Probability of Treatment Weighting		
	Palbociclib +		Standardized Difference
	Letrozole (n=715)	Letrozole (n=547)	
Age, y			
Mean (SD)	66.2 (11.9)	67.1 (14.9)	0.0716
Median (IQR)	67.0 (59.0–75.0)	68.0 (59.0–76.0)	
Age group, ^a n (%), y			
18–64	295 (41.2)	221 (40.4)	–0.0168
65–74	232 (32.4)	178 (32.6)	0.0036
≥75	188 (26.3)	148 (27.0)	0.0149
Race/ethnicity, ^a n (%)			
White	501 (70.1)	364 (66.5)	–0.0761
Black	47 (6.5)	39 (7.1)	0.0218
Asian	15 (2.1)	15 (2.8)	0.0448
Hispanic or Latino	15 (2.1)	16 (2.9)	0.0488
Other/unknown	137 (19.2)	113 (20.7)	0.0384
Practice type, ^a n (%)			
Academic	37 (5.1)	26 (4.8)	0.0155

Community	678 (94.9)	521 (95.2)	
Disease stage at initial diagnosis, ^a n (%)			
I or II	254 (35.5)	171 (31.3)	-0.0884
III	103 (14.4)	80 (14.62)	0.0053
IV	284 (39.7)	230 (42.1)	0.0496
Not documented	74 (10.4)	65 (12.0)	0.0488
ECOG PS, ^a n (%)			
0	257 (36.0)	193 (35.3)	-0.0139
1	147 (20.5)	118 (21.6)	0.0267
2	47 (6.5)	36 (6.6)	0.0029
3 or 4	12 (1.7)	9 (1.6)	-0.0025
Not documented	252 (35.3)	190 (34.8)	-0.0097
Visceral disease, ^a n (%)			
No	436 (60.9)	342 (62.5)	-0.0313
Yes	279 (39.1)	205 (37.5)	
Bone-only disease, ^{a,b} n (%)			
	270 (37.7)	210 (38.4)	0.0129
Brain metastases, n (%)			
	21 (3.0)	17 (3.2)	0.0118
Number of metastatic sites, ^{a,c} n (%)			
1	361 (50.5)	278 (50.8)	0.0073
2	196 (27.5)	156 (28.6)	0.0253
3	89 (12.5)	65 (11.8)	-0.0200

≥4	40 (5.6)	29 (5.4)	-0.0119
Not documented	28 (4.0)	19 (3.4)	-0.0306

ECOG=Eastern Cooperative Oncology Group; IQR=interquartile range.

^aVisceral disease was defined as metastatic disease in the lung and/or liver; patients could have had other sites of metastases. No visceral disease was defined as no lung or liver metastases.

^bBone-only disease was defined as metastatic disease in only the bone.

^cMultiple metastases at the same site were counted as 1 site (eg, if a patient had 3 bone metastases in the spine, it was considered only 1 site).